| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Avantor, Inc.$11.84
+0.4 (+3.45%)
Market Cap
5.54 B
EPS
-0.81
P/E Ratio
-
Value Trade
60.52 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.58 B
Operating CF
58.70 M
Total Assets
11.66 B
Total Liabilities
6.07 B
Equity
5.59 B
D/E Ratio
12,345
2.53 %
Week
-5.36 %
1 Month
-12.5 %
3 Month
-26.71 %
6 Month
-74.15 %
5 Year
-44.84 %
All Time
Cash Data
Cash Position
282.20 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 29, 2026
Overview
Volume
9.03 M
52 Week Range
7.27 - 15.93
% held by Insiders
3.06 %
% held by Institutions
100 %
Enterprise Value
9.08 B
Total Shares
682.89 M
Short %
8.46 %
Float Shares
672.65 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Avantor, Inc.
1Total events
1Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Upcoming catalysts 1
TBD
T2Quarterly Update
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AVTR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AVTR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AVTR▲ +6.9%on this news
Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product
Avantor's NuSil brand has expanded its partnership with the Population Council to develop a three-month dapivirine vaginal ring for HIV prevention. This new product aims to improve adherence and convenience, requiring only four rings per year. The collaboration highlights Avantor's commitment to innovative healthcare solutions, although the product is still under regulatory review.
Read more →AVTRCell Culture Media Market worth $12.9 billion by 2033: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
The global cell culture media market is expected to grow from $5.3 billion in 2026 to $12.9 billion by 2033, driven by the increasing demand for biologics and cell therapies. Key factors include the shift towards serum-free and chemically defined media, which enhance production efficiency and regulatory compliance. North America leads the market, while Asia Pacific shows the fastest growth potential.
Read more →AVTRAvantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026
Avantor, Inc. has announced that it will release its second quarter 2026 financial results on July 29, 2026, before the market opens. A conference call will follow at 8:00 a.m. EDT to discuss these results. The company emphasizes its role in supporting critical research and development activities globally.
Read more →AVTRAvantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
Avantor, Inc. has appointed Gerard (Jerry) Porreca as Executive Vice President of Quality and Regulatory. He will oversee quality assurance and regulatory affairs globally. Porreca has significant experience in the life sciences and healthcare sectors, previously leading quality initiatives at Getinge and other companies. His expertise is expected to enhance Avantor's operations and customer solutions.
Read more →AVTRAvantor Reports First Quarter 2026 Results Net sales of $1,581 million Net income of $43 million Adjusted EBITDA of $219 million Diluted GAAP EPS of $0.06 adjusted EPS of $0.17 Operating cash flow of $59 million free cas
Avantor, Inc. reported its first-quarter 2026 financial results, highlighting net sales of $1,581 million and a net income of $43 million. The results indicated that the performance exceeded expectations, particularly in the Bioscience and Medtech product areas. However, the company noted a decline in organic net sales primarily due to foreign currency adjustments. Despite a decrease in net income compared to the previous year, Avantor reaffirmed its fiscal 2026 guidance, suggesting confidence in its operational stability.
Read more →AVTR▼ -6.3%on this news
Avantor® Announces Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer
Avantor, Inc. has appointed Ludovic Brellier as Executive Vice President for Bioscience & Medtech Products and Chief Transformation Officer, effective May 1, 2026. Brellier, who previously led business units at Cytiva, will focus on enhancing operational performance and driving transformation initiatives. His leadership is expected to unlock growth potential within Avantor's BMP segment.
Read more →AVTRAvantor® Enhances U.S. Biomanufacturing Infrastructure with Expanded Stability and Microbial Testing Facility
Avantor, Inc. has announced the expansion of its St. Louis manufacturing site to include advanced microbial and stability testing. This enhancement aims to strengthen U.S. biopharma manufacturing support and improve supply chain efficiency. The facility is designed to meet global regulatory standards, ensuring high-quality service and faster product development timelines.
Read more →AVTRAvantor® to Report First Quarter 2026 Earnings on Wednesday, April 29, 2026
Avantor, Inc. has announced the release date for its first quarter 2026 earnings report, which will occur before the market opens on April 29, 2026. Following the release, a conference call will be held at 8:00 a.m. EDT to discuss the results. Investors can access the live audio webcast on Avantor's website.
Read more →AVTRAvantor® Announces CFO Transition
Avantor, Inc. has announced the upcoming departure of CFO R. Brent Jones, effective on or before June 24, 2026. To ensure continuity, Steve Eck, the current Senior Vice President and Chief Accounting Officer, will take over as interim CFO. The company has also reaffirmed its financial guidance for 2026.
Read more →AVTR▼ -13.6%on this news
Avantor® Reports Fourth Quarter and Full Year 2025 Results
Avantor, Inc. reported its financial results for Q4 and the full year 2025, revealing a decrease in net sales and a significant net loss. The company is implementing a Revival program aimed at improving its operational agility and market competitiveness. Despite the challenges, Avantor's leadership expresses confidence in their strategic initiatives for future growth.
Read more →AVTRAvantor® to Participate in 44th Annual J.P. Morgan Healthcare Conference
Avantor, Inc. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, where CEO Emmanuel Ligner will present on January 14, 2026. The event is significant for showcasing advancements in life sciences and technology. A live audio webcast will be available, with a replay accessible for 30 days.
Read more →AVTR▼ -23.2%on this news
Avantor Reports Third Quarter 2025 Results Net sales of $1.62 billion, decrease of 5% Net loss of $712 million and diluted GAAP loss per share of $1.04, including a non-cash goodwill impairment charge of $785 million Adj
Avantor, Inc. reported a net loss of $712 million for the third quarter of 2025, significantly down from a net gain of $57.8 million the previous year. The company experienced a 5% decrease in net sales to $1.62 billion, including a major non-cash goodwill impairment charge. Despite these challenges, Avantor announced a $500 million share repurchase program and reported an adjusted EBITDA of $268 million, reflecting ongoing operational activity. The management is implementing changes to its strategies to enhance performance and shareholder value.
Read more →AVTR▼ -15.5%on this news
Avantor Reports Second Quarter 2025 Results Net sales of $1.68 billion, decrease of 1% organic revenue was flat Net income of $65 million Adjusted EBITDA of $280 million Diluted GAAP EPS of $0.09 adjusted EPS of $0.24 Op
Avantor, Inc. reported its second quarter 2025 financial results, revealing net sales of $1.68 billion, a 1% decrease from the previous year. Net income fell to $65 million, down from $92.9 million a year ago, while adjusted EBITDA stood at $280 million. The company saw revenue growth in its Laboratory Solutions segment and secured major contracts, although performance was impacted by planned maintenance and regulatory challenges in the Bioscience Production segment. Changes in leadership were also announced, with new CEO Emmanuel Ligner set to take over in August 2025.
Read more →AVTR▼ -7.1%on this news
Avantor Announces Emmanuel Ligner as Next President and CEO Seasoned Executive with Proven Track Record of Value Creation in Life Sciences RADNOR, Pa.
Avantor, Inc. has announced the appointment of Emmanuel Ligner as its new President and CEO, effective August 18, 2025. Ligner, who has over 30 years of experience in the life sciences sector, succeeds Michael Stubblefield. He previously led Cytiva and held a significant role at GE Life Sciences, indicating a strong background in driving growth and leadership. The Board expressed confidence that Ligner will guide Avantor towards achieving its strategic objectives in Lab Solutions and Bioscience Production.
Read more →AVTR▼ -16.6%on this news
Avantor Reports First Quarter 2025 Results Net sales of $1.58 billion, decrease of 6% organic decline of 2% Net income of $64.5 million Adjusted EBITDA of $269.5 million Diluted GAAP EPS of $0.09 adjusted EPS of $0.23 Op
Avantor, Inc. reported its financial results for the first quarter of 2025, revealing a net sales decline of 6% year-over-year, totaling $1.58 billion. Despite an increase in net income to $64.5 million, the company's performance was affected by decreased demand in the Education and Government sectors. In response, Avantor is implementing strategic actions to enhance its cost structure, targeting $400 million in gross run-rate savings by the end of 2027. The company remains confident in its long-term value creation potential, even amidst challenging market conditions.
Read more →AVTR▼ -11.7%on this news
Avantor Reports Fourth Quarter and Full Year 2024 Results Fourth Quarter 2024 Net sales of $1.69 billion, decrease of 2% organic growth of 1% Net income of $500.4 million Adjusted EBITDA of $307.7 million Diluted GAAP EP
Avantor, Inc. has reported its fourth quarter and full year 2024 results, showing net sales of $1.69 billion, a decrease of 2%. Despite this decline, the company experienced significant increases in net income and adjusted EBITDA, showcasing a strong recovery from the previous year. The company expects ongoing momentum driven by its innovative strategies and operational efficiency. However, net sales and organic growth showed some weaknesses due to factors like foreign currency translation and a Clinical Services divestiture.
Read more →AVTRAvantor Reports Third Quarter 2024 Results Net sales of $1.71 billion, decrease of 0.3% organic decline of 0.7% Net income of $57.8 million Adjusted EBITDA of $302.5 million Diluted GAAP EPS of $0.08 adjusted EPS of $0.2
Avantor, Inc. reported its third quarter 2024 financial results, revealing net sales of $1.71 billion, a slight decline of 0.3% year-over-year. The company experienced a drop in net income, now at $57.8 million compared to $108.4 million from the previous year. Despite these declines, there were positive indicators in the bioprocessing and laboratory solutions segments, showing potential for growth. Avantor's CEO stated that the company remains focused on long-term growth and has raised its free cash flow guidance for the year.
Read more →AVTRAvantor® Enters into Definitive Agreement to Divest Clinical Services Business to Audax Private Equity
Avantor, Inc. has signed a definitive agreement to divest its clinical services business to Audax Private Equity for approximately $650 million. This move is part of Avantor's strategy to optimize its portfolio and focus on growth opportunities in its lab and production sectors. The transaction is expected to close in Q4 2024, pending regulatory approvals.
Read more →AVTR▲ +12.2%on this news
Avantor Reports Second Quarter 2024 Results Net sales of $1.70 billion, decrease of 2.4% organic decline of 2.0% Net income of $93 million Adjusted EBITDA of $306 million Diluted GAAP EPS of $0.14 adjusted EPS of $0.25 O
Avantor, Inc. reported its financial results for the second quarter of 2024, showing net sales of $1.70 billion, which reflects a 2.4% decline compared to the same period in 2023. Despite the decrease in sales, net income rose significantly to $93 million from a loss in the prior year. The company reported an adjusted EBITDA of $306 million, reflecting a sequential improvement driven by a better mix of bioprocessing revenue and cost transformations. Avantor reaffirmed its fiscal year 2024 guidance amidst ongoing strategic initiatives.
Read more →AVTRAvantor Reports First Quarter 2024 Results Net sales of $1.68 billion, decrease of 5.6% organic decline of 6.3% Net income of $60 million Adjusted EBITDA of $283 million Diluted GAAP EPS of $0.09 adjusted EPS of $0.22 Op
Avantor Inc. reported its Q1 2024 financial results, revealing net sales of $1.68 billion, reflecting a 5.6% decline compared to the previous year. The company's net income also fell to $60 million from $121.5 million in Q1 2023. Despite the decrease in sales and net income, the company reported an adjusted EBITDA of $283 million, indicating profitability. The CEO expressed optimism about market stability and the effectiveness of their cost transformation initiatives.
Read more →AVTR▲ +10.2%on this news
Avantor Reports Fourth Quarter and Full-Year 2023 Results Fourth Quarter 2023 Net sales of $1.72 billion, decrease of 4.0% core organic decline of 4.8% Net income of $98.5 million Adjusted EBITDA of $302.1 million Dilute
Avantor, Inc. reported a decline in net sales for Q4 2023, totaling $1.72 billion, down 4.0% year-over-year, with an adjusted EBITDA of $302.1 million. The company's full-year net sales also fell by 7.3% to $6.97 billion, alongside reduced net income from $321.1 million in the previous year. However, Avantor noted that free cash flow exceeded guidance, achieving over 120% conversion. Despite some encouraging signs in the market, company leadership emphasized the absence of a notable inflection point in business performance.
Read more →AVTRAvantor Hosts Investor Day, Announces New Strategic Operating Model to Drive Growth and Productivity Transformative New Operating Model to Feature Two Complementary Business Segments Al
Avantor, Inc. recently hosted an Investor Day to unveil a new strategic operating model aimed at enhancing growth and productivity. The new model will streamline the company into two business segments: Laboratory Solutions and Bioscience Production. Additionally, Avantor announced a cost optimization initiative targeting $300 million in savings by the end of 2026, while reaffirming its fiscal guidance for 2023. The structural changes will take effect on January 1, 2024, along with new leadership appointments in key roles.
Read more →AVTR▼ -8.7%on this news
Avantor Reports Third Quarter 2023 Results Net sales of $1.72 billion, decrease of 7.3% core organic decline of 7.9% Net income of $108.4 million Adjusted EBITDA of $317.8 million Diluted GAAP EPS of $0.16 adjusted EPS o
Avantor, Inc. reported its third quarter 2023 financial results, revealing net sales of $1.72 billion, down 7.3% from the previous year's third quarter. The company's net income decreased significantly to $108.4 million, a drop from the $167 million recorded in Q3 2022. Despite these declines, Avantor achieved strong operating cash flow of $230.7 million and highlighted its ongoing debt reduction efforts, having repaid over $650 million year to date. President and CEO Michael Stubblefield expressed confidence in the company's long-term strategy and operational performance.
Read more →AVTR▼ -6.8%on this news
Avantor Reports Second Quarter 2023 Results Net sales of $1.74 billion, decrease of 8.7% core organic decline of 6.5% Net income of ($7.3) million Adjusted EBITDA of $343.0 million Diluted GAAP EPS of ($0.01) adjusted EP
Avantor, Inc. reported its second quarter 2023 financial results, revealing a net sales decline of 8.7% to $1.74 billion and a net income loss of $7.3 million. The adjusted EBITDA of $343 million was in line with company guidance, reflecting their efforts to control costs and enhance productivity despite challenging market conditions, particularly in biopharma. The company also noted the negative impact of a significant non-cash impairment charge related to its Ritter assets. Despite these challenges, Avantor remains committed to long-term strategies and continues to invest in growth opportunities.
Read more →AVTRAvantor Names R. Brent Jones as Chief Financial Officer RADNOR, Pa.
Avantor, Inc. has appointed R. Brent Jones as its new Executive Vice President and Chief Financial Officer, effective August 7, 2023. Mr. Jones brings nearly 30 years of financial experience in life sciences and is expected to lead Avantor's global finance organization. He takes over from Thomas A. Szlosek, who will transition to a new role outside the industry. Jones highlighted Avantor's strong market position and expressed excitement to work with the leadership team to drive growth and shareholder value.
Read more →AVTRAvantor® Launches Responsible Supplier Program
Avantor, Inc. has launched its Responsible Supplier Program aimed at reducing environmental impact and promoting sustainability in its supply chain. The program, which began piloting in 2022, focuses on six key priorities including climate change and human rights. Avantor emphasizes collaboration with suppliers to tackle sustainability challenges and has committed to setting emissions reduction targets in line with climate science.
Read more →AVTRAvantor Announces CFO Transition RADNOR, Pa.
Avantor, a leading global provider of mission-critical products and services, announced that CFO Thomas A. Szlosek will leave the company effective August 2, 2023, to pursue a new opportunity outside the life sciences industry. Szlosek will remain in his role until the announcement of the company's second quarter earnings. Avantor has begun the search for a new CFO while reaffirming its fiscal 2023 financial guidance. The company credits Szlosek for his contributions in expanding their global enterprise since going public in 2019.
Read more →AVTRAvantor Reports First Quarter 2023 Results Net sales of $1.78 billion, decrease of 8.7% core organic decline of 1.8% Net income of $121.5 million Adjusted EBITDA of $346.2 million Diluted GAAP EPS of $0.18 adjusted EPS o
Avantor, Inc. reported its Q1 2023 financial results, revealing net sales of $1.78 billion, down 8.7% from the previous year. Despite a core organic sales decline of 1.8%, the company’s management expressed optimism regarding long-term market fundamentals and its growth strategy. Adjusted EBITDA was reported at $346.2 million, with a notable decrease in net income to $121.5 million. The company attributes some challenges to ongoing inventory destocking and foreign currency impacts while maintaining plans for innovation and market expansion.
Read more →AVTR▼ -7.4%on this news
Avantor Reports Fourth Quarter and Full-Year 2022 Results Fourth Quarter Net sales of $1.80 billion, decrease of 5.9% core organic growth of 2.7% Net income of $141.7 million Adjusted EBITDA of $359.5 million Diluted GAA
Avantor, Inc. reported its fourth quarter and full-year 2022 financial results, revealing a net sales decrease of 5.9% in Q4 while achieving a core organic growth of 2.7%. The full-year net sales grew by 1.7%, driven by robust performance in bioproduction, which saw over 20% core organic growth. Despite challenges from macroeconomic pressures and customer destocking, Avantor noted strong margin expansion and an increase in net income for the year. The company's adjusted EBITDA margin also improved, showcasing resilient operational performance.
Read more →AVTR▼ -6.4%on this news
Avantor Reports Third Quarter 2022 Results Net sales of $1.86 billion, increase of 1.2% core organic net sales growth of 7.8% Net income of $167.0 million Adjusted EBITDA of $384.0 million Diluted GAAP EPS of $0.25 adjus
Avantor Reports Third Quarter 2022 Results Net sales of $1.86 billion, increase of 1.2% core organic net sales growth of 7.8% Net income of $167.0 million Adjusted EBITDA of $384.0 million Diluted GAAP EPS of $0.25 adjusted EPS of $0.34 Operating cash flow of $258.3 million f
Read more →AVTRAvantor Reports Second Quarter 2022 Results Net sales of $1.91 billion, increase of 2.8% core organic net sales growth of 6.4% Net income of $187.4 million Adjusted EBITDA of $404.1 million Diluted GAAP EPS of $0.28 adju
Avantor Reports Second Quarter 2022 Results Net sales of $1.91 billion, increase of 2.8% core organic net sales growth of 6.4% Net income of $187.4 million Adjusted EBITDA of $404.1 million Diluted GAAP EPS of $0.28 adjusted EPS of $0.37 Operating cash flow of $227.5 million
Read more →AVTRAvantor Reports First Quarter 2022 Results Net sales of $1.95 billion, increase of 9.2% organic net sales growth of 5.1% Net income of $190.4 million Adjusted EBITDA of $423.1 million Diluted GAAP EPS of $0.28 adjusted E
Avantor Reports First Quarter 2022 Results Net sales of $1.95 billion, increase of 9.2% organic net sales growth of 5.1% Net income of $190.4 million Adjusted EBITDA of $423.1 million Diluted GAAP EPS of $0.28 adjusted EPS of $0.38 Operating cash flow of $152.2 million free c
Read more →AVTRAvantor Reports Fourth Quarter and Full-Year 2021 Results Fourth Quarter Net sales of $1.91 billion, increase of 6.5% organic net sales growth of 2.5% Net income of $94.0 million Adjusted EBITDA of $369.8 million Diluted
Avantor Reports Fourth Quarter and Full-Year 2021 Results Net sales of $1.91 billion, increase of 6.5% organic net sales growth of 2.5% Net income of $94.0 million Adjusted EBITDA of $369.8 million Diluted GAAP EPS of $0.13 adjusted EPS of $0.36 Operating cash flow of $301.0
Read more →AVTRAvantor Reports Third Quarter 2021 Results Net sales of $1.83 billion, increase of 14.3% organic revenue growth of 10.2% Net income of $156.8 million Adjusted EBITDA of $359.2 million Diluted GAAP EPS of $0.24 adjusted E
Avantor Reports Third Quarter 2021 Results Net sales of $1.83 billion, increase of 14.3% organic revenue growth of 10.2% Net income of $156.8 million Adjusted EBITDA of $359.2 million Diluted GAAP EPS of $0.24 adjusted EPS of $0.35 Operating cash flow of $261.9 million free c
Read more →AVTRAvantor Announces Offering of Senior Notes RADNOR, Pa.
Avantor Announces Offering of Senior Notes RADNOR, Pa., Oct. 19, 2021 Avantor, Inc. (NYSE: AVTR) ( Avantor ), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials industries, announce
Read more →AVTRAvantor Reports Second Quarter 2021 Results Net sales of $1.86 billion, increase of 25.7% organic net sales growth of 20.5% Net income of $157.8 million Adjusted EBITDA of $366.6 million Diluted GAAP EPS of $0.24 adjuste
Avantor Reports Second Quarter 2021 Results Net sales of $1.86 billion, increase of 25.7% organic net sales growth of 20.5% Net income of $157.8 million Adjusted EBITDA of $366.6 million Diluted GAAP EPS of $0.24 adjusted EPS of $0.35 Operating cash flow of $263.8 million fre
Read more →AVTRAvantor Reports First Quarter 2021 Results Revenue of $1.79 billion, increase of 17.5% organic revenue growth of 13.5% Net income of $164.0 million Adjusted EBITDA of $363.1 million Diluted GAAP EPS of $0.25 adjusted EPS
Avantor Reports First Quarter 2021 Results Revenue of $1.79 billion, increase of 17.5% organic revenue growth of 13.5% Net income of $164.0 million Adjusted EBITDA of $363.1 million Diluted GAAP EPS of $0.25 adjusted EPS of $0.35 Operating cash flow of $126.9 million free cas
Read more →AVTRAvantor Reports Fourth Quarter and Full-Year 2020 Results Business Highlights Q4 revenue of $1.791 billion, up 17.5% organic revenue growth of 14.9% Q4 Adjusted EBITDA $319.9 million, expansion of 60 basis points Q4 EPS
Avantor Reports Fourth Quarter and Full-Year 2020 Results Q4 revenue of $1.791 billion, up 17.5% organic revenue growth of 14.9% Q4 Adjusted EBITDA $319.9 million, expansion of 60 basis points Q4 EPS of $0.06 adjusted EPS of $0.29, growth of 57.2% Q4 Operating Cash Flow $306
Read more →AVTRAvantor Announces Upsizing and Pricing of Offering of 650.0 Million of Senior First Lien Notes RADNOR, Pa.
Avantor Announces Upsizing and Pricing of Offering of 650.0 Million of Senior RADNOR, Pa., Oct. 30, 2020 - Avantor, Inc. (NYSE: AVTR) ( Avantor ), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and ap
Read more →AVTRAvantor Announces Offering of Senior First Lien Notes
Avantor Announces Offering of Senior First Lien Notes RADNOR, Pa., Oct. 28, 2020 - Avantor, Inc. (NYSE: AVTR) ( Avantor ), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industri
Read more →AVTRAvantor Announces Upsizing and Pricing of Offering of $2.0 Billion Equivalent of Senior Notes RADNOR, Pa.
Avantor Announces Upsizing and Pricing of Offering of $2.0 Billion Equivalent of Senior Notes RADNOR, Pa., July 7, 2020 /PRNewswire/ Avantor, Inc. (NYSE: AVTR) ( Avantor ), a leading global provider of mission critical products and services to customers in the life sciences an
Read more →AVTRINDEX TO FINANCIAL STATEMENTS VWR CORPORATION Glossary 2 Audited Consolidated Financial Statements as of
INDEX TO FINANCIAL STATEMENTS VWR CORPORATION Glossary 2 Audited Consolidated Financial Statements as of December 31, 2016 and 2015 and for each of the three years in the period ended December 31, 2016 Report of Independent Registered Public Accounting Firm 3 Consolid
Read more →AVTRAvantor Reports First Quarter 2020 Results Revenue of $1.52 billion, increase of 2.6%; organic growth of 4.1% Net income of $47 million; Adjusted EBITDA $262.8 million, increase of 6% Diluted GAAP EPS $0.05; adjusted EPS
Avantor Reports First Quarter 2020 Results Radnor, Pa. - April 29, 2020 - Avantor, Inc. (NYSE: AVTR), a leading global provider of mission critical products and services to customers in the life sciences and advanced technologies & applied materials industries, today reported fi
Read more →AVTRAvantor Reports Fourth Quarter and Full-Year 2019 Results Net sales $1.52 billion, net income $70.6 million, adjusted EBITDA $263.6 million Diluted GAAP EPS $0.09; adjusted EPS $0.19, up 89.9% Operating cash flow $87.0 m
Avantor Reports Fourth Quarter and Full-Year 2019 Results Radnor, Pa. - February 7, 2020 - Avantor, Inc. (NYSE: AVTR), a leading global provider of mission critical products and services to customers in the life sciences and advanced technologies & applied materials industries,
Read more →AVTRAvantor Reports Third Quarter 2019 Results Net sales of $1.50 billion, net income of $22.1 million, adjusted EBITDA of $250.8 million GAAP earnings per share of $0.01, adjusted EPS of $0.15, up 49% Operating cash flow of
Avantor Reports Third Quarter 2019 Results Radnor, Pa. - November 5, 2019 - Avantor, Inc. (NYSE: AVTR), a leading global provider of mission critical products and services to customers in the life sciences and advanced technologies & applied materials industries, today reported
Read more →AVTRAvantor Reports Second Quarter 2019 Results Net sales of $1.53 billion, up 4% (6% on an organic basis) Net loss of $(48.7) million, adjusted net income 1 of $91.6 million, up 60% GAAP loss per share of $(0.98), pro forma
Avantor Reports Second Quarter 2019 Results Radnor, PA - August 6, 2019 - Avantor, Inc. (NYSE: AVTR), a leading global provider of mission critical products and services to customers in the life sciences and advanced technologies & applied materials industries, today reported fi
Read more →Competitive Position
How AVTR ranks across every disease it competes inCompetitive Position is a premium feature
See how AVTR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial